Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when LBRX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsLB Pharmaceuticals reports Q1 2026 earnings in routine disclosure
Filed May 12, 2026 · Period ending May 12, 2026 · ~1 min read
Key Changes
-
high
Company issued press release announcing financial results for quarter ended March 31, 2026. Actual figures and performance metrics are contained in the attached exhibit, not in the 8-K body itself.
Item 2.02 verify on EDGAR → -
medium
This is a standard quarterly earnings announcement filing with no unusual procedural elements or additional material events disclosed.
8-K: Earnings view on EDGAR →
Summary
LB Pharmaceuticals filed its routine quarterly earnings 8-K on May 12, 2026, announcing first quarter 2026 financial results through an attached press release. The filing follows standard Item 2.02 disclosure requirements for public companies reporting quarterly performance. The 8-K itself contains minimal detail, with actual financial figures, revenue, earnings, and management commentary contained in the press release exhibit.
Retail investors should review the attached press release for the complete financial picture, including revenue trends, profitability metrics, and any forward guidance management provided. This is a procedural filing with no red flags or unusual elements. Watch for the upcoming 10-Q filing, which will provide full financial statements, footnotes, and management's discussion and analysis offering deeper context on the quarter's performance and business outlook.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
LB Pharmaceuticals announced Q1 2026 financial results via press release on May 12, 2026.
Added in current filing · verify on EDGAR →
On May 12, 2026, LB Pharmaceuticals Inc (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026.
The company disclosed its first quarter 2026 financial results through a press release. The 8-K filing itself does not contain the actual financial figures or performance metrics, which are contained in the attached press release exhibit. This is a standard earnings announcement filing under Item 2.02.
Event · Item 9.01 — Financial Statements and Exhibits
LB Pharmaceuticals filed an 8-K attaching a press release dated May 12, 2026; no material event details disclosed in the filing body.
Added in current filing · verify on EDGAR →
Press Release dated May 12, 2026.
The 8-K references an attached press release dated May 12, 2026, but does not disclose the content or subject matter of the release within the filing body itself. Without the exhibit text, the materiality and nature of the disclosed event cannot be determined from this filing.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 10, 2026 · How we verify